The life science market in 2026 is characterized by cautious optimism amid technological transformation and selective growth. An aging population and rising disease prevalence fuel healthcare demand, while regulatory uncertainty, funding fluctuations, slower biotech IPOs, and softening life science real estate create headwinds. This ETS brief profiles the key market players and the current challenges, and notes the stabilization of venture capital around companies with strong innovation and clinical success.
It summarizes the key trends — AI-driven drug discovery and automation reshaping R&D cycles, Medicare price negotiations under the Inflation Reduction Act and evolving FDA frameworks, and portfolio streamlining with increased M&A — alongside the geographic shift toward Asia-Pacific and three digital imperatives: workforce upskilling, legacy system modernization, and process digitalization.
The second half maps SAP solutions to the sector's supply chain challenges: global disruptions, regulatory compliance, demand variability, raw material shortages, manufacturing complexity, technology integration, talent shortages, and cybersecurity, drawing on SAP ERP Cloud, SAP IBP, quality management, and SuccessFactors.
The full brief is available above as a PDF. For the three-page summary see the "2026 Life Science Market Fact Sheet", and for the complete 19-page deck see the "2026 Life Science Market Overview" in the Resource Library.